The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Anti-BCMA CAR T-cell therapy in CNS-involved myeloma: safety and long-term outcomes
Sven Neubert, MD, University Hospital Wuerzburg, Wuerzburg, Germany, discusses findings from a multicenter real-world study evaluating anti-BCMA CAR T-cell therapy in 25 patients with relapsed/refractory multiple myeloma and central nervous system (CNS) involvement. Dr Neubert highlights encouraging response rates and manageable neurotoxicity with idecabtagene vicleucel and ciltacabtagene autoleucel, while emphasizing the challenges of relapse, response durability, and the potential importance of CNS disease control before infusion. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
